SCHEMBL5067710

SCHEMBL5067710

COc1ccc(N)c(-c2ccn[nH]c2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLK2 Q86UE8 1/20 0.46
NOTUM Q6P988 1/20 0.46
NPC1 O15118 3/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 3/20 0.42
SCN4A P35499 1/20 0.41
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
GFER P55789 1/20 0.40
PDE4B Q07343 1/20 0.40
CYP3A4 P08684 2/20 0.40
TYMS P04818 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
CYP2C19 P33261 1/20 0.40
CYP19A1 P11511 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18770626 0.84 TLK2 (0.50) TLK2NOTUMNPC1RAB9AALDH1A1
SCHEMBL30295727 0.79 NOTUM (0.49) TLK2NOTUMNPC1RAB9AALDH1A1
SCHEMBL5070317 0.78 GAA (0.48) TLK2NOTUMNPC1RAB9AALDH1A1
SCHEMBL30206743 0.77 ALDH1A1 (0.61) NPC1RAB9AALDH1A1GAAMAPK1
SCHEMBL30206740 0.77 ALDH1A1 (0.61) NPC1RAB9AALDH1A1GAAMAPK1
SCHEMBL11004268 0.77 ALDH1A1 (0.61) NPC1RAB9AALDH1A1GAAMAPK1
SCHEMBL14484688 0.76 SCN4A (0.59) NOTUMNPC1RAB9ASCN4AGAA
SCHEMBL5070312 0.76 HSD17B1 (0.44) TLK2NOTUMNPC1RAB9AALDH1A1
SCHEMBL5067708 0.75 ALDH1A1 (0.53) ALDH1A1GAAHTTCYP3A4CHEK1
Hydrochloric Acid SCHEMBL30014997 0.75 SCN4A (0.57) NOTUMNPC1RAB9ASCN4AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234301-A1 Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-09-25 US disclosed
EP-1737826-A1 ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES TANABE SEIYAKU CO., LTD. (JP) 2007-01-03 EP disclosed
WO-2005075438-A1 ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES TANABE SEIYAKU CO., LTD. (JP) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234301-A1 Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases ITGB4, ITGA4, ICAM1 TLK2 2546/4885NOTUM 3886/4885NPC1 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.